Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers (original) (raw)
Miller WE, Raab-Traub N. The EGFR as a target for viral oncoproteins. Trends Microbiol 1999; 7: 453–8 ArticlePubMedCAS Google Scholar
Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241–50 ArticlePubMedCAS Google Scholar
Hutcheson IR, Gee JMW, Barrow D, et al. Endocrine resistance in breast cancer can involve a switch towards EGFR signalling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839. Signal Transduction Pathways and Regulation of Gene Expression as Therapeutic Targets: 2000 Jan 26–29; Luxembourg, 125
Sainsbury JRC, Farndon JR, Needham GK, et al. Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1987; I: 1398–402 Google Scholar
Nicholson S, Richard J, Sainsbury C, et al. Epidermal growth factor receptor (EGFr): results of a 6-year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 1991; 63: 146–50 ArticlePubMedCAS Google Scholar
Iihara K, Shiozali H, Tahara E, et al. Prognostic significance of transforming growth factor alpha in human esophageal carcinoma. Cancer 1993; 71: 2902–9 ArticlePubMedCAS Google Scholar
Pavelic K, Bankac Z, Pavelic J, et al. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993; 13: 1133–7 PubMedCAS Google Scholar
Perry JE, Grossmann ME, Tindall DJ. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate 1998; 35: 117–24 ArticlePubMedCAS Google Scholar
Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838–48 PubMedCAS Google Scholar
He Y, Zeng Q, Drenning SD, et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 1998; 90: 1080–7 ArticlePubMedCAS Google Scholar
De Jong JS, van Diest PJ, van der Valk P, et al. Expression of growth factors, growth-inhibiting factors and their receptors in invasive breast cancer: II. Correlations with proliferation and angiogenesis. J Pathol 1998; 184: 53–7 ArticlePubMed Google Scholar
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–64 ArticlePubMedCAS Google Scholar
Prakash I, Mathur RP, Kar P, et al. Comparative evaluation of cell proliferative indices and epidermal growth factor receptor expression in gastric carcinoma. Indian J Pathol Microbiol 1997;40:481–90 PubMedCAS Google Scholar
Fry DW Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 1999; 82: 207–18 ArticlePubMedCAS Google Scholar
Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther 1999; 82: 195–206 ArticlePubMedCAS Google Scholar
Prewett M, Rockwell P, Rockwell RF, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996; 19: 419–27 ArticlePubMedCAS Google Scholar
Overholser JP, Prewett MC, Hooper AT, et al. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000; 89: 74–82 ArticlePubMedCAS Google Scholar
Yang XD, Jia X-C, Corvalan RF, et al. Therapeutic potential of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer treatment [abstract]. Proc Annu Meet Am Soc Clin Oncol 2000; 19: 48 Google Scholar
Uckun FM, Narla RK, Jun X, et al. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. Clin Cancer Res 1998;4:901–12 PubMedCAS Google Scholar
Uckun FM, Narla FM, Zeren T, et al. In vivo toxicity, pharmacokinetics and anticancer activity of genistein linked to recombinant human epidermal growth factor. Clin Cancer Res 1998; 4: 1125–34 PubMedCAS Google Scholar
Hirao T, Sawada T, Koyama F, et al. Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer. Cancer Gene Ther 1999; 6:423–7 ArticlePubMedCAS Google Scholar
Witters L, Kumar R, Mandal M, et al. Antisense oligonucleotides to the epidermal growth factor receptor. Breast Cancer Res Treat 1999;53:41–50 ArticlePubMedCAS Google Scholar
Woodburn JR, Barker AJ, Gibson KH, et al. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development [abstract 4251]. Proc Am Assoc Cancer Res 1997; 38: 633 Google Scholar
Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291: 739–48 PubMedCAS Google Scholar
Medina L, Gomez L, Cerna C, et al. Investigation of the effects of the tyrosine kinase (TK) inhibitor CI-1033 (PD0183805) against human tumour specimens taken directly from patient [abstract]. Proc Am Assoc Cancer Res 2000; 41: 483 Google Scholar
Brans CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signalling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60: 2926–35 Google Scholar
O’Reilly T, Cozens R, Traxler P. In vivo antitumor activity of the epidermal growth factor receptor (EGFR) inhibitor PKI166 [abstract]. Proc Am Assoc Cancer Res 2000; 41: 481 Google Scholar
Lavelle F. American Association for Cancer Research 1997:progress and new hope in the fight against cancer. Expert Opin Invest Drags 1997;6:771–5 ArticleCAS Google Scholar
Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drags activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053–63 PubMedCAS Google Scholar
Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD 1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with five selected tumor types: evidence of activity and good tolerability [abstract]. Proc Annu Meet Am Soc Clin Oncol 2000; 19: A686 Google Scholar
Ferry D, Hammond L, Ranson M, et al. Intermittent oral ZD 1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a Phase I study [abstract]. Proc Annu Meet Am Soc Clin Oncol 2000; 19: A5E Google Scholar